A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives

(2015) Paolo Pellegrino et al.   AUTOIMMUNITY REVIEWS

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival

(2015) C. M. Reed et al.   CLINICAL CANCER RESEARCH

Development of a Quantitative Real-Time RT-PCR Assay for the Detection of MAGE-A3–Positive Tumors

(2015) Olivier Gruselle et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Nonclinical reproductive and developmental safety evaluation of the MAGE-A3 Cancer Immunotherapeutic, a therapeutic vaccine for cancer treatment

(2015) E. Destexhe et al.   REPRODUCTIVE TOXICOLOGY

Non-clinical safety evaluation of single and repeated intramuscular administrations of MAGE-A3 Cancer Immunotherapeutic in rabbits and cynomolgus monkeys

(2014) Eric Destexhe et al.   JOURNAL OF APPLIED TOXICOLOGY

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide

(2013) Elise P. Salerno et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

(2013) Wim H.J. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

(2012) Nadeem A. Sheikh et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

(2012) P. Sabbatini et al.   CLINICAL CANCER RESEARCH

Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine

(2011) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells

(2011) M. K. L. MacLeod et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2009) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy

(2009) Preeta Tyagi et al.   Clinical Lung Cancer

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

(2008) Craig L. Slingluff et al.   ANNALS OF SURGICAL ONCOLOGY

Functional Specializations of Human Epidermal Langerhans Cells and CD14+ Dermal Dendritic Cells

(2008) Eynav Klechevsky et al.   IMMUNITY

Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens

(2008) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

(2008) D. Atanackovic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers

(2008) Pierre Vandepapelière et al.   VACCINE